Marisa Wexler, MS, senior science writer —

No connection is evident between exposure to the dental amalgam used to fill cavities and the risk of developing Sjögren’s syndrome,  a study by researchers in Taiwan reported. The study, “Analysis of dental amalgam fillings on primary Sjögren’s syndrome,” was published in Medicine.  Dental amalgam is…

Telitacicept (RC18), an experimental therapy being developed by RemeGen, significantly eased disease activity in people with primary Sjögren’s syndrome in a Phase 2 clinical trial, the company announced. “We are very excited to see the positive results from the Phase II clinical trial of telitacicept,” Jianmin Fang,…

Combining the anti-inflammatory medicines hydrocortisone and ciclosporin A could help ease eye symptoms in people with Sjögren’s syndrome, according to a new study. The study, “Efficacy of Topical Hydrocortisone in Combination with Topical Ciclosporin A for the Treatment of Dry Eye Disease in Patients with Sjögren…

A clinical trial at the University of Texas Southwestern Medical Center in Dallas is currently recruiting people with autoimmune diseases, particularly Sjögren’s syndrome, who also have postural orthostatic tachycardia syndrome (POTS). The study, supported by a $150,000 joint grant from the Sjögren’s Foundation and Dysautonomia International, is…

Note: This story was updated Dec. 21, 2021, to note that Sjögren’s syndrome is not a rare disease, being estimated to affect 1-4 million people in the United States. While the vast majority of people with Sjögren’s syndrome are satisfied with their healthcare provider and medication, more than one…

Mesenchymal stem cells (MSCs), traditionally found in the bone marrow of adults, may help treat Sjögren’s syndrome by improving saliva production and decreasing inflammation, but the underlying processes of these cells need to be studied further, according to a research review. The paper, “Treatment of Sjögren’s…

The Sjögren’s Foundation has given it 2021 Outstanding Abstract Award to two scientists who presented new research about Sjögren’s syndrome at this year’s annual meeting of the American College of Rheumatology. The award “recognizes exceptional research and encourages investigators to continue to focus on Sjögren’s throughout their career,”…

The Sjögren’s Foundation, a nonprofit health organization focused on increasing research, education, and awareness about Sjögren’s syndrome, has announced its most dedicated volunteers who were honored recently at the foundation’s 2021 Virtual National Patient Conference. “Every year, the Foundation recognizes our most dedicated volunteers through awards that are…

The findings of a new study support the development of Incyte‘s parsaclisib as a potential therapy for Sjögren’s syndrome and other autoimmune diseases. Parsaclisib, an oral inhibitor of phosphatidylinositol 3-kinase (PI3K) delta, was found to ease the symptoms of Sjögren’s and other disorders in a study using mouse models.

A new method for dividing people with primary Sjögren’s syndrome (pSS) into subgroups based on detailed molecular differences may help improve precision treatment for patients, a recent study suggests. The findings “have major implications for the treatment of pSS patients,” researchers wrote, as they could help unravel the causes…